Search all articles within the Institute for Biomedicine and Glycomics topic
Salivary biomarkers could be the way forward in diagnosing liver fibrosis thanks to a partnership between Griffith University and Gallipoli...
A world-first trial to help improve the lives of Australians living with a debilitating spinal cord injury is a step closer with a $6.8 million Medical Research Future Fund grant.
A next-generation COVID-19 mucosal vaccine is set to be a gamechanger not only when delivering the vaccine itself, but also for people who are needle-phobic.
Professor Paul Clarke will join the University as the inaugural Executive Director of the new Institute for Biomedicine and Glycomics.
A $2 million grant awarded to establish the Queensland Drug Discovery Alliance (QDDA) will align and grow Queensland’s small molecule therapeutic discovery capability under the leadership of Therapeutic Innovation Australia (TIA).
In a groundbreaking effort to combat the devastating effects of Spinal Muscular Atrophy (SMA), Dr. Jean Giacomotto from the Griffith...
Native Charge Detection Mass Spectrometry will enable cross-collaboration research to develop life-changing therapies, vaccines and diagnostics.
Griffith University has been awarded $2.2 million across the National Health and Medical Research Council (NHMRC) Investigator Grants. Congratulations to...
Griffith researchers among 19 scientists share in $5.56 million of funding.
Researchers develop drug target to tackle multi-drug resistant lung bacterium.
